Year: 2023

SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand. Under the terms of the agreement, LianBio will receive a one-time payment of $25 million. In addition, LianBio is eligible to receive a sales milestone payment of $5 million. Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer...

China Shenzhen, Dec. 25, 2023 (GLOBE NEWSWIRE) — (Sina News Agency) On December 20, 2023, Wing Tiger International Block Chain Technology Co., Ltd., the holding company of American Global Group (stock code: TGGI), and China Energy Aoyin Capital (Hong Kong) Co., Ltd. officially signed a cooperation agreement on artificial intelligence technology and blockchain technology. The strategic cooperation agreement on R&D and operations confirms the in-depth cooperative relationship of mutual trust between the two parties. The main content of this strategic cooperation is: Wing Tiger International Block Chain Technology Co., Ltd will officially become the global operator of the artificial intelligence products (Lianxin APP, Shuan quantum encryption software and hardware) of Zhongneng Aoyin Capital (Hong Kong) Company suppliers and...

Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facilityThe CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon. The CRL did not state any concerns about the clinical data package or safety of dasiglucagon.Copenhagen, Denmark, December 23, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for...

Company announcement no. 31 / 2023Schindellegi, Switzerland – 23 December 2023 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 November 2023 up to and including no later than 31 March 2024. For details, please see announcement no. 17 of 31 October 2023. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 15 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 232,497 treasury shares, corresponding to 1.2% of the share capital. Under the program, the following transactions have been...

TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 14.2023 23.12.2023 TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds Capitalised terms used but not defined are used with the meanings given to them in the Terms and Conditions (as defined below). TRESU Investment Holding A/S gives notice to the holders of its Senior Secured Floating Rate Bonds 2017/2027 with ISIN no. DK0030404967 (the “Bonds”) issued pursuant to the terms and conditions originally dated 22 September 2017 as last amended and restated on 22 December 2023 (the “Terms and Conditions“) that the Interest Payment Test has not been met in respect of the Interest Payment Date on 29 December 2023 and that it will settle the payment of Interest that should have been made on 29 December 2023 by issuance of Interest Bonds in accordance...

VANCOUVER, British Columbia, Dec. 22, 2023 (GLOBE NEWSWIRE) — Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) announced today that the Board of Directors has approved the grant of 1,713,750 incentive stock options (“Options”) under the Company’s long-term incentive plan. The grants were made to employees, officers, directors, and consultants of the Company. The Options entitle the holders to purchase the equivalent number of common shares of the Company at a price of $0.72 per common share for a period of five years from the date of grant. The options granted to employees will vest as follows: 25% on the date of grant, followed by an additional 25% each six months thereafter. All grants of Options are subject to the Company’s Stock Option Plan which was approved by shareholders at Mirasol’s annual...

Toronto, Ontario, Dec. 22, 2023 (GLOBE NEWSWIRE) — Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company, specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to produce various derivative cannabis 2.0 and 3.0 products in the medical and recreational market, is pleased to provide the following corporate updates. Annual General and Special Meeting The Company is pleased to announce that its voting results from its annual general and special meeting of shareholders of the Company (the “Shareholders”) held on December 20, 2023 (the “Meeting”). Shareholders voted in favour of each resolution put forward at the Meeting at a passing rate of over 96%, including approval of each of the Future Share Issuance Resolution...

MONTREAL, Dec. 22, 2023 (GLOBE NEWSWIRE) — (TSX-V: HAR) (“Harfang” or the “Company”) is pleased to announce that it has completed a non-brokered private placement for gross proceeds of $940,500 (the “Private Placement”). Pursuant to the Private Placement, Harfang issued an aggregate of (a) 2,733,333 flow-through common shares as a part of a charity arrangement (the “Charity FT Shares”) at $0.30 per Charity FT Share and (b) 573,811 flow-through common shares (the “FT Shares”) at $0.21 per FT Share. “We are excited to welcome a new institutional shareholder to Harfang and would like to thank the continued support of our existing shareholders participating in this placement,” said Rick Breger, President. “With this additional liquidity, we further reinforce our optionality and financial flexibility. We, at Harfang, are all looking...